AR072510A1 - Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana - Google Patents
Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humanaInfo
- Publication number
- AR072510A1 AR072510A1 ARP090102680A ARP090102680A AR072510A1 AR 072510 A1 AR072510 A1 AR 072510A1 AR P090102680 A ARP090102680 A AR P090102680A AR P090102680 A ARP090102680 A AR P090102680A AR 072510 A1 AR072510 A1 AR 072510A1
- Authority
- AR
- Argentina
- Prior art keywords
- linear
- branched
- alkyl
- phenyl
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas y usos como inhibidores de la enzima SCD-1. Reivindicacion 1: Derivados de la 2H-[1,2,4]triazin-3,5-diona y de la H-pirimidin-2,4-diona para su uso como inhibidores de la actividad de la enzima SCD-1 y que corresponden a la formula general (1), en la que: W representa el nitrogeno o CH; R1 y R2 representan independientemente uno del otro: i) un hidrogeno o un radical alquilo o alquenilo lineal o ramificado en C1-7, o ii) un radical alquilo en C1-3 sustituido con unos grupos tales como: trifluorometilo, nitrilo, hidroxi, alcoxi en C1-3; alcoxialcoxi en C3-6, indolilo, tiofenilo, oxotiofenilo, N-alquilo o N-dialquilcarbamoilo en C1-3 o, fenilo o aroilo o benciloxi o N-arilcarbamoilo (para los cuales el nucleo fenilo está eventualmente sustituido con uno o varios grupos tales como alquilo lineal o ramificado en C1-4, nitro, halogeno), iii) un grupo fenilo o piridilo o naftilo o tiofenilo eventualmente sustituido con uno o varios grupos tales como halogeno, nitro, nitrilo, trifluorometilo, vinilo metilsulfanilo, alquilo lineal o ramificado en C1-4, alcoxi lineal o ramificado en C1-3, fenilo, N-mono o dialquilcarbamoilo en C1-3, alquilcarboxamido en C1-4, iv) un radical 2-oxocicloalquilo en C5-6 eventualmente condensado con un grupo fenilo; m es igual a 0 o 1; V representa CH2, CHCH3 o C=O; cuando n = 1, X-Y representa -N-(C=O)-, -N-CH2-, -CH-CH2-, -CH-O-, CH-(C=O)-, Z representa un grupo fenilo eventualmente sustituido con uno o varios grupos trifluorometilo, halogeno, alquilo lineal o ramificado en C1-4, alcoxi lineal o ramificado en C1-3; cuando n = 0, X representa N, Z representa un grupo fenilo o cinnamilo o ariloxicarbonilo o 2-fenilacetilo (cuya posicion 2 está eventualmente sustituida por un alcoilo lineal o ramificado en C1-4) para los cuales el aromático está eventualmente sustituido con uno o varios grupos trifluorometilo, halogeno, alquilo lineal o ramificado en C1-4, alcoxi lineal o ramificado en C1-3, nitro; así como las sales de adicion con las bases y los ácidos farmacéuticamente aceptables, y los diferentes enantiomeros de los compuestos que poseen unos carbonos asimétricos, así como sus mezclas en cualquier proporcion que comprenden en particular las mezclas racémicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0854794A FR2933979B1 (fr) | 2008-07-15 | 2008-07-15 | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072510A1 true AR072510A1 (es) | 2010-09-01 |
Family
ID=40394394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102680A AR072510A1 (es) | 2008-07-15 | 2009-07-15 | Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8618287B2 (es) |
| EP (1) | EP2328886B1 (es) |
| JP (1) | JP5599788B2 (es) |
| AR (1) | AR072510A1 (es) |
| FR (1) | FR2933979B1 (es) |
| TW (1) | TW201006815A (es) |
| WO (1) | WO2010006962A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5540454B2 (ja) | 2009-12-30 | 2014-07-02 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | ジペプチジルペプチダーゼ阻害剤 |
| FR2958935B1 (fr) * | 2010-04-19 | 2012-06-22 | Pf Medicament | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine |
| CN104803971B (zh) * | 2014-01-24 | 2021-11-30 | 深圳信立泰药业股份有限公司 | 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物 |
| CN105017213B (zh) * | 2014-04-30 | 2017-11-14 | 成都苑东生物制药股份有限公司 | 尿嘧啶衍生物 |
| JP6814730B2 (ja) * | 2014-09-05 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EP3566055A4 (en) | 2017-01-06 | 2020-12-02 | Yumanity Therapeutics, Inc. | TREATMENT METHODS FOR NEUROLOGICAL DISORDERS |
| EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| US11203587B2 (en) * | 2018-10-12 | 2021-12-21 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| US20230089582A1 (en) | 2019-11-26 | 2023-03-23 | Kpc Pharmaceuticals, Inc | 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof |
| WO2024102455A1 (en) * | 2022-11-09 | 2024-05-16 | Emory University | Non-covalent inhibitors of coronavirus main protease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5973573A (ja) * | 1982-09-09 | 1984-04-25 | ワ−ナ−−ランバ−ト・コンパニ− | ジアミノピリミジン化合物 |
| BR0315166A (pt) * | 2002-10-11 | 2005-08-16 | Astrazeneca Ab | Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento |
| FR2866339B1 (fr) * | 2004-02-18 | 2006-05-05 | Pf Medicament | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
| WO2007071023A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
-
2008
- 2008-07-15 FR FR0854794A patent/FR2933979B1/fr not_active Expired - Fee Related
-
2009
- 2009-07-07 US US13/054,293 patent/US8618287B2/en not_active Expired - Fee Related
- 2009-07-07 WO PCT/EP2009/058609 patent/WO2010006962A1/en active Application Filing
- 2009-07-07 JP JP2011517863A patent/JP5599788B2/ja not_active Expired - Fee Related
- 2009-07-07 EP EP09797466.1A patent/EP2328886B1/en not_active Not-in-force
- 2009-07-10 TW TW098123438A patent/TW201006815A/zh unknown
- 2009-07-15 AR ARP090102680A patent/AR072510A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2328886B1 (en) | 2016-12-28 |
| JP5599788B2 (ja) | 2014-10-01 |
| WO2010006962A1 (en) | 2010-01-21 |
| TW201006815A (en) | 2010-02-16 |
| JP2011528007A (ja) | 2011-11-10 |
| EP2328886A1 (en) | 2011-06-08 |
| US8618287B2 (en) | 2013-12-31 |
| FR2933979B1 (fr) | 2012-08-24 |
| FR2933979A1 (fr) | 2010-01-22 |
| US20110118266A1 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072510A1 (es) | Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| AR075243A1 (es) | Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
| PE20060921A1 (es) | Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales | |
| AR070836A1 (es) | Derivados de carbazol inhibidores de hsp90, composiciones que los contie-nen; utilizacion de los compuestos para preparar medicamentos; un proce-dimiento para la preparacion de los compuestos; medicamentos; y compues-tos intermediarios de sintesis | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| GT200800258A (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| AR075892A1 (es) | Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| AR066014A1 (es) | Difenil- dihidro -imidazopiridinonas. composiciones farmaceuticas y usos. | |
| RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR031867A1 (es) | Compuestos derivados de fenoxibencilamina como ssri, su uso en la preparacion de medicamentos, procedimiento de preparacion del compuesto e intermediarios utiles | |
| AR075874A1 (es) | Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacion | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones | |
| AR077301A1 (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b | |
| AR054121A1 (es) | Compuestos de fenilpiridilpiperazina, procedimiento de preparacion, composiciones farmaceuticas que los contienen, y usos farmacologicos como antagonistas de receptores histaminergicos h3 | |
| AR072103A1 (es) | Derivados de (piperazinilo con enlaces puente)-1- alcanona, su utilizacion como inhibidores de p75 y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |